EUCTR2009-014446-28-IT进行中（未招募）不适用
A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER - THE JANUS TRIA
IVERSITA` CAMPUS BIOMEDICO0 个研究点开始时间: 2009年12月14日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Men with histological diagnosis of prostate cancer
- •Stage T1c or T2a disease AND PSA value of 10 ng/ml or less AND a Gleason score of 6 or less
- •Men older than 75 years OR life expectancy of less than 10 years: PSA can be greater than 10 ng/ml OR the Gleason score can be 7 (3 + 4)
- •Age ≥ 18 years
- •WHO performance status 0-2
- •Written informed consent to all required assessments
- •Patients must have undergone a core biopsy for the diagnosis of their prostate cancer
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •T0, T1a,b, T2b,c, T3 tumours AND/OR Gleason > 7 AND/OR PSA > 10 if life expectancy > 10 years
- •Previous hormone or radiotherapy to the treated prostate
- •Evidence of metastatic disease or recurrent prostate cancer
- •Previous diagnosis of malignancy unless
- •onon-melanomatous skin cancer
- •Serum creatinine > 1.5 x upper limit of normal reference range or calculated creatinine clearance <40 mls/min
- •Prior treatment with bisphosphonates in the last year
- •Requiring anticoagulation with warfarin or coumarin derivatives
- •Known hypersensitivity to bisphosphonates
- •Current active dental problems including dental abcess or infection of the jawbone (maxilla or mandible) or a current or prior diagnosis of osteonecrosis of the jaw
- •Recent (within 4 weeks) or planned dental or jaw surgery (recent dental fillings, teeth scaling, polishing or minor gingival surgery do not exclude the patient)
- •History of bone metabolism diseases
- •History of active acute and/or chronic inflammatory diseases
- •Fever (> 37.5 C) in the two weeks before the study enter
- •Concomitant prolonged treatment with steroids (either IV or oral)
研究者
相似试验
招募中
1 期
A Translational Phase 1B, 2-Part Study to Evaluate Pharmacokinetics, Safety and Pharmacodynamics of Treatment with ATX-304 Na Salt Tablets.Obesity with prediabetes or type 2 diabetes mellitusMedDRA version: 23.0Level: LLTClassification code: 10082306Term: Cardiometabolic syndrome Class: 10027433CTIS2023-505967-36-00Betagenon AB72
已完成
不适用
An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR)HER2-negative metastatic breast cancerJPRN-UMIN000029590West Japan Oncology Group51
进行中（未招募）
不适用
MULTICENTER PHASE II STUDY FOR THE EVALUATION OF BEVACIZUMAB, OXALIPLATIN AND CAPECITABINE IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER - BOXEEUCTR2010-019463-10-ITAZIENDA OSPEDALIERA S. CARLO44
进行中（未招募）
1 期
A Study to Assess the Relative Bioavailability of Roxadustat Azo Dye-free Tablet in Healthy SubjectsHealthy Adult Volunteers (intended indication is anemia associated with chronic kidney disease (CKD))MedDRA version: 20.0 Level: LLT Classification code 10002272 Term: Anemia System Organ Class: 100000004851EUCTR2018-002924-18-DEAstellas Pharma Global Development, Inc. (APGD)24
撤回
2 期
A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated with Pamiparib in Subjects with Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or carcinosarcoma who have progressed on P-gp substrate chemotherapy or PARP inhibitors with the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 ReversioHigh Grade Serous Ovarian CancerCarcinosarcomaCancer - Ovarian and primary peritonealACTRN12619000583145Australia New Zealand Gynaecological Oncology Group40